Skip to main content

Table 1 Patient demographics and baseline disease characteristics (N = 30 patients)

From: Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

Variable No. of patients (%)
Age (years; Median (range) 61 (37–76)
Cutaneous primary 21 (70)
Unknown primary 8 (27)
Mucosal 1 (3)
Gender
 Female 12 (40)
 Male 18 (60)
Performance status
 0 16 (53)
 1 14 (47)
Recurrent disease after prior surgery 15 (50)
Presence of in-transit metastases 16 (53)
Prior adjuvant HDI 5 (17)
Estimated risk Stage
 IIIB 3 (10)
 IIIC 25 (83)
 IV (Not eligible) 2 (7)